USFDA inspects Baroda plant, no observations issued: Alembic

Published On 2017-04-18 05:48 GMT   |   Update On 2017-04-18 05:48 GMT

New Delhi : Alembic Pharmaceuticals said no observations were issued by US health regulator USFDA after inspection of its Baroda facility.


The bio-equivalence facility was inspected by US Food & Drug Administration (USFDA) from March 6-10; March 13-17 and April 10-12, Alembic said in a filing to BSE.


"There were no 483s issued by USFDA at the end of the inspection," it added.


USFDA issues Form 483 observations to a firm's management at the conclusion of an inspection to notify it of objectionable conditions at the facility.


It is issued when investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.


Alembic stock was trading at Rs 626.80, up 0.35 per cent, in the afternoon trade on BSE.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News